Table 2.
Distribution of serologic responses following SARS-CoV-2 vaccination regarding patient characteristics, type of cancer, and treatment.
| SARS-CoV-2 Spike Protein Positive (%) | COVID-19 Neutralizing Antibody Positive (%) | Either SARS-CoV-2 Spike Protein or Neutralizing Antibody Positive (%) | |
|---|---|---|---|
| Age | |||
| <40 years | 17 (73.9%) | 16 (69.6%) | 19 (82.6%) |
| 40-60 years | 71 (89.9%) | 72 (91.1%) | 76 (96.2%) |
| >60 years | 14 (82.4%) | 16 (94.1%) | 16 (94.1%) |
| P value | 0.143 | 0.015 | 0. 072 |
| Stage | |||
| I | 3 (75.0%) | 4 (100%) | 4 (100.0%) |
| II | 29 (87.9%) | 29 (87.9%) | 32 (97.0%) |
| III | 64 (85.3%) | 66 (88.0%) | 69 (92.0%) |
| IV | 6 (85.7%) | 5 (71.4%) | 6 (85.7%) |
| P value | 0.917 | 0.526 | 0. 606 |
| Treatment 1 | |||
| Chemotherapy +/- RT | 18 (66.7%) | 19 (70.4%) | 21 (77.8%) |
| Radiotherapy | 19 (95.0%) | 19 (95.0%) | 20 (100.0%) |
| Follow up including Endocrine therapy, Trastuzumab | 65 (90.3%) | 66 (91.7%) | 70 (97.2%) |
| P value | 0.005 | 0.009 | 0.001 |
| Treatment 2 | |||
| Follow up + Endocrine therapy | 35 (89.7%) | 39 (100.0%) | 39 (100.0%) |
| Follow up + Endocrine + Trastuzumab | 3 (75.0%) | 3 (75.0%) | 3 (75.0%) |
| Follow Up | 28 (93.3%) | 25 (83.3%) | 29 (96.7%) |
| P value | 0.494 | 0.020 | 0.014 |
Bold text indicates a statistically significant difference with a p-value less than 0.05.